Study design and ethics
This was a three‐arm, double‐blind, randomized parallel‐group controlled trial. It was conducted from December 2022 to March 2023 at Damascus University. This study was approved by the ethics board at Damascus University (N 725/2022) and was conducted in accordance with Helsinki Declaration 2013 and CONSORT statement. Written informed consent was provided by the patients' legal guardians. This study was registered in Australian New Zealand Clinical Trials Registry (ACTRN12623000567628).